Franco Laghi Pasini

Franco Laghi Pasini

Auto-generated profile, based on publicly available information

Franco Laghi Pasini

Department of Medical Sciences, Surgery and Neurosciences University of Siena Italy

Research Focus & Metrics

Academic Career Length

51Years (1976-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SASyed Sohail Ahmed
Syed Sohail Ahmed
WVWayne Volkmuth
Wayne Volkmuth
JDJosé Duca
José Duca
LCLorenzo Corti
Lorenzo Corti
MPMichele Pallaoro
Michele Pallaoro
LSLawrence Steinman
Lawrence Steinman
Similarity between influenza nucleoprotein and hypocretin receptor 2 may trigger vaccine-associated narcolepsy.

6 February 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ABAngelika Banzhoff
Angelika Banzhoff
RGRoberto Gasparini
Roberto Gasparini
FLFranco Laghi-Pasini
Franco Laghi-Pasini
TSTommaso Staniscia
Tommaso Staniscia
PDPaolo Durando
Paolo Durando
APAudino Podda
Audino Podda
Pathogenic avian influenza virus (H5N1) has the potential to cause a major global pandemic in humans. Safe and effective vaccines that induce immunologic memory and broad heterotypic response are needed. Healthy adults aged 18–60 and >60 years (n = 313 and n = 173, respectively) were randomized (1∶1) to receive two primary and one booster injection of 7.5 μg or 15 μg doses of a subunit MF59-adjuvanted H5N1 (A/Vietnam/1194/2004) (clade 1) vaccine. Safety was monitored until 6 months after booster. Immunogenicity was assessed by hemagglutination inhibition (HI), single radial hemolysis (SRH) and microneutralization assays (MN). Mild injection-site pain was the most common adverse reaction. No serious adverse events relating to the vaccine were reported. The humoral immune responses to 7.5 μg and 15 μg doses were comparable. The rates for seroprotection (HI>40; SRH>25mm2; MN ≥40) after the primary vaccination ranged 72–87%. Six months after primary vaccination with the 7.5 μg dose, 18% and 21% of non-elderly and elderly adults were seroprotected; rates increased to 90% and 84%, respectively, after the booster vaccination. In the 15 μg group, seroprotection rates among non-elderly and elderly adults increased from 25% and 62% after primary vaccination to 92% and 88% after booster vaccination, respectively. A heterologous immune response to the H5N1/turkey/Turkey/05 strain was elicited after second and booster vaccinations. Both formulations of MF59-adjuvanted influenza H5N1 vaccine were well tolerated. The European Union requirement for licensure for pre-pandemic vaccines was met by the lower dose tested. The presence of cross-reactive antibodies to a clade 2 heterologous strain demonstrates that this vaccine may be appropriate for pre-pandemic programs. ClinicalTrials.gov NCT00311480

6 December 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AAAdemuyiwa S. Aromolaran
Ademuyiwa S. Aromolaran
USUjala Srivastava
Ujala Srivastava
AAAlessandra Alí
Alessandra Alí
MCMohamed Chahine
Mohamed Chahine
DLDeana Lazaro
Deana Lazaro
MBMohamed Boutjdir
Mohamed Boutjdir
Increased proinflammatory interleukin-6 (IL-6) levels are associated with acquired long QT-syndrome (LQTS) in patients with systemic inflammation, leading to higher risks for life-threatening polymorphic ventricular tachycardia such as Torsades de Pointes. However, the functional and molecular mechanisms of this association are not known. In most cases of acquired LQTS, the target ion channel is the human ether-á-go-go-related gene (hERG) encoding the rapid component of the delayed rectifier K current, IKr, which plays a critical role in cardiac repolarization. Here, we tested the hypothesis that IL-6 may cause QT prolongation by suppressing IKr. Electrophysiological and biochemical assays were used to assess the impact of IL-6 on the functional expression of IKr in HEK293 cells and adult guinea-pig ventricular myocytes (AGPVM). In HEK293 cells, IL-6 alone or in combination with the soluble IL-6 receptor (IL-6R), produced a significant depression of IKr peak and tail current densities. Block of IL-6R or Janus kinase (JAK) reversed the inhibitory effects of IL-6 on IKr. In AGPVM, IL-6 prolonged action potential duration (APD) which was further prolonged in the presence of IL-6R. Similar to heterologous cells, IL-6 reduced endogenous guinea pig ERG channel mRNA and protein expression. The data are first to demonstrate that IL-6 inhibition of IKr and the resulting prolongation of APD is mediated via IL-6R and JAK pathway activation and forms the basis for the observed clinical QT interval prolongation. These novel findings may guide the development of targeted anti-arrhythmic therapeutic interventions in patients with LQTS and inflammatory disorders.

27 January 2005 in The FASEB Journal
Verified
Journal Article
Closed access
PDF file
RGRaffaella Ghittoni
Raffaella Ghittoni
Laura PatrussiLaura Patrussi
Laura Patrussi
KPKatja Pirozzi
Katja Pirozzi
MPMichela Pellegrini
Michela Pellegrini
PLPietro E. Lazzerini
Pietro E. Lazzerini
CBCosima T. Baldari
Cosima T. Baldari

1 August 2007 in Autoimmunity Reviews
Verified
Journal Article
Closed access
PLPietro Enea Lazzerini
Pietro Enea Lazzerini
PCPier Leopoldo Capecchi
Pier Leopoldo Capecchi
ESEnrico Selvi
Enrico Selvi
SLSauro Lorenzini
Sauro Lorenzini
SBStefania Bisogno
Stefania Bisogno
FPFranco Laghi Pasini
Franco Laghi Pasini

20 February 2008 in Diabetologia
Verified
Journal Article
Closed access
PDF file
CEC. G. Egan
C. G. Egan
RLR. Lavery
R. Lavery
FCF. Caporali
F. Caporali
CFC. Fondelli
C. Fondelli
FLF. Laghi-Pasini
F. Laghi-Pasini
Vincenzo SorrentinoVincenzo Sorrentino
Vincenzo Sorrentino